Short answer
Insulet Corporation (PODD) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $762M (up 33.9% year over year) with net income of $91M.
Q1 2026 key financials · XBRL
- Revenue
- $762M
- +33.9% YoY
- Net income
- $91M
- +157.3% YoY
- Operating margin
- 16.0%
- Gross margin
- 69.5%
- EPS (diluted)
- $1.30
- +160.0% YoY
Source: XBRL data from the Insulet Corporation (PODD) Q1 2026 10-Q on SEC EDGAR. USD.
Insulet Corporation Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $761.7M, up 33.9% YoY from $569.0M, driven by Omnipod Products growth
- Gross margin 69.5% vs 71.9% YoY, pressured by inventory reserves and warranty costs
- International Omnipod revenue $242.9M, up 59.4%; worst line Drug Delivery $3.3M vs $14.9M
- Operating cash flow $113.8M vs $63.8M; free cash flow $89.5M vs $51.6M
- Cash $480.4M vs $716.1M; $300.0M share repurchases and $24.3M capital expenditures
- 2026 outlook: strong U.S. growth and higher international revenue; correction costs approximately $30M
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- Regulatory risk carried forward without quarterly updates
- Operational and competitive risks unchanged from the 2025 Form 10-K
- Financial risks, including liquidity and debt exposure, unchanged from the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Insulet Corporation quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.